Cytokinetics presents aficamten data at cardiology congress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- Wall Street ends down as oil prices, Treasury yields rise
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil settles up around 4% as Iran's president vows to never surrender
- Wall Street ends down as oil prices, Treasury yields rise
- Anthropic's Claude AI identifies novel enzyme system in DNA search
- AppLovin (APP) on watch amid 3% drop premarket as boutique comments circulate
- Plug Power COO resigns to join another company
- Xtend AI Robotics wins Phase III of USSOCOM lethal drone program
Cytokinetics Presents New Data Related to Aficamten at the European Society of Cardiology Congress 2025
August 31, 2025 12:10 PM EDTAdditional Data from MAPLE-HCM Shows Aficamten Improves Cardiac Structure and Function Compared to Metoprolol; Simultaneous Publication in the Journal of the American College of Cardiology
New Analysis Shows Annual Incidence Rate of Atrial Fibrillation with Aficamten is 1.5%, Consistent with Expected Rates in Prediction Model of Patients with HCM; Simultaneous Publication in Heart Rhythm
Longer-Term Data Presented Consistent with Previously Reported Safety Profile of Aficamten
Company to Host Investor Event and Webcast Tuesday September 2, 2025, at 8:30 AM Eastern Time
SOUTH SAN... More
